Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis

Journal of Crohn's & Colitis
Deborah S HartmanBarbara S Fox

Abstract

AVX-470 is an orally administered, bovine-derived, anti-tumour necrosis factor (TNF) antibody with local activity in the gastrointestinal tract. In the first-in-human clinical trial of AVX-470 in active ulcerative colitis, we evaluated inflammatory biomarkers in colon tissue as measures of disease activity and early response to treatment. Thirty-six patients received active drug (AVX-470 at 0.2, 1.6 or 3.5g/day) or placebo over 4 weeks. Colon biopsy samples were collected from 5 regions of colon at baseline and week 4. Tissue inflammatory biomarkers were evaluated by immunohistochemistry and quantitative reverse transcription-polymerase chain reaction (qRT-PCR), epithelial cell apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) and bovine immunoglobulin by immunohistochemistry and mass spectrometry. Endoscopic activity (Ulcerative Colitis Endoscopic Index of Severity [UCEIS]) at colonoscopy was assessed in each colonic region by a central reader. Bovine immunoglobulin was observed in mucosal tissue before and after dosing in lamina propria and submucosal layers of biopsy tissue. Baseline levels of TNF, myeloperoxidase (MPO), CD68 and interleukin (IL)-1β and, to a lesser extent, IL-6 mRNA were 2- ...Continue Reading

References

Dec 24, 1987·The New England Journal of Medicine·K W SchroederD M Ilstrup
Jul 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Marco MariniFabio Cominelli
Mar 3, 2007·The Journal of Clinical Investigation·Warren StroberPeter Mannon
Jul 27, 2007·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·C HassanS Morini
Sep 14, 2007·Scandinavian Journal of Gastroenterology·Trine OlsenJon Florholmen
Dec 5, 2009·Scandinavian Journal of Gastroenterology·Jakob Benedict Seidelin, Ole Haagen Nielsen
Jun 3, 2010·World Journal of Gastroenterology : WJG·Franco ScaldaferriSilvio Danese
Aug 21, 2010·Inflammatory Bowel Diseases·Sa'ad Y Salim, Johan D Söderholm
Jul 31, 2013·Gastroenterology·Simon P L TravisWilliam J Sandborn
Aug 21, 2013·Inflammatory Bowel Diseases·Kailash C BholBarbara S Fox
Feb 1, 2014·Alimentary Pharmacology & Therapeutics·T LobatónP Rutgeerts
May 14, 2014·International Immunology·Moritz LeppkesChristoph Becker
Jul 22, 2014·Alimentary Pharmacology & Therapeutics·B S BolandJ T Chang
Aug 12, 2014·Gastroenterology Clinics of North America·Mark A SamaanBarrett G Levesque
Sep 16, 2014·Inflammatory Bowel Diseases·Fermín Sánchez de MedinaOlga Martínez-Augustin
Mar 4, 2015·Scandinavian Journal of Gastroenterology·Øyvind HausoHelge Waldum
Mar 19, 2015·The New England Journal of Medicine·Giovanni MonteleoneFrancesco Pallone

❮ Previous
Next ❯

Citations

Jun 23, 2016·Expert Opinion on Biological Therapy·Lieven PouillonLaurent Peyrin-Biroulet
Oct 31, 2018·Advances in Therapy·Roni WeisshofDavid T Rubin
Nov 7, 2019·Pharmaceutical Development and Technology·Faten MadaniPierre Tchoreloff
May 13, 2018·International Journal of Molecular Sciences·Sophie SteelandRoosmarijn E Vandenbroucke
Jun 18, 2020·Pharmaceutics·Bahez GarebJos G W Kosterink
Oct 26, 2018·Advanced Drug Delivery Reviews·A BakD J Brayden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis